Top Back to top

Physicians Webinars

Upcoming webinars from EBMT

Thrombotic Microangiopathy –associated with HSCT (TA-TMA)

REGISTRATION OPEN!

Register now to this live webinar on 11 May, from 15:00 to 16:00 CEST, click HERE and complete the webform.

The webinar will be hosted by Dr Enric Carreras and moderated by Dr Olaf Penack.

This seminar aims to transmit to the audience the basic knowledge about transplant associated thrombotic microangiopathy, from its pathogenesis to its diagnosis, differential diagnosis, management and treatment.

Learning objective:

  • The basic objective is that the audience learns to suspect and diagnose as soon as possible this complication.

How to treat chronic Graft-versus-Host Disease in 2021 (PDWP)

REGISTRATION OPEN!

Register now to this live webinar on 20 May, from 16:00 to 16:45 CEST, click HERE and complete the webform.


The webinar is organized by the Paediatric Diseases Working Party (PDWP). It will be hosted by Dr Daniel Wolff and moderated by Dr Jörg Halter.

This recorded webinar will give you an overview on First- and Second line treatment principles and options of chronic GVHD. 

A week before the webinar the prerecorded video will be upload to this webpage. You should watch it and prepare your questions for the live event.

 

Update on diagnostic and treatment of severe combined immunodeficiencies (IEWP)

REGISTRATION OPEN!

Register now to this live webinar on 25 May, from 16:00 to 17:30 CEST, click HERE and complete the webform.


The webinar is organized by the Inborn Errors Working Party (IEWP).

Programme:
  • New born screening in SCID (Marjam van der Burg)
  • HSCT approaches in SCID (Manfred Hoenig)
  • Gene therapy in SCID (Claire Booth)
  • Q&A (Moderated by: Bénédicte Neven and Arjan Lankaster)
Learning objectives:
  • To learn about neonatal screening of SCID 
  • How to manage transplant in this disease especially in the future with implementation of newborn screening?
  • What is the place of gene therapy?
Speaker panel:

Moderators:

  • Bénédicte Neven, MD, PhD. Necker Children Hospital, Université de Paris, Paris, France.
  • Arjan C Lankester, professor of Paediatrics and Stem Cell Transplantation. Willem-Alexander Children’s Hospital. Paediatric Stem Cell Transplantation Program. Leiden University Medical Center. The Netherlands.

Speakers:

  • Mirjam van der Burg, PhD. Associate Professor Primary Immunodeficiencies. Dept. of Pediatrics, Laboratory for Pediatric Immunology. Willem Alexander Children’s Hospital, Leiden University Medical Center.
  • Manfred Hoenig. Assistant Professor Dr. University Medical Center Ulm University, Department of Pediatrics, Ulm, Germany.
  • Claire Booth. Associate Professor in Gene Therapy, UCL GOS Institute of Child Health. Consultant in Paediatric Immunology, Great Ormond Street Hospital. UK.

Past webinars

  

Haplo-Identical HSCT, Methods and Practices Around the Globe (EBMT&WBMT)

This webinar, jointly organized by EBMT and WBMT, summarized the different platforms developed around the world to perform haploidentical transplants.

Programme:
  • Opening remarks
  • Haploidentical HSCT practice in Europe. Andrea Bacigalupo (Italy) 
  • Haploidentical HSCT practice in Asia. Xiao-Jun Huang (China)
  • Haploidentical HSCT practice in North America. Leo Luznik (USA)
  • Q&A Live Session
Learning objectives:
  • To describe the global transplant rates and trends in haploidentical SCT
  • To summarize the platforms developed in China, Europe and the USA to perform haploidentical SCT
  • To review outcome data in comparison to other donor sources
Speaker panel:

Moderators:

  • Nicolaus Kröger, MD. Professor of Medicine. EBMT President. Director Department of Stem Cell Transplantation. University Hospital Hamburg-Eppendorf. Germany.
  • Univ. Prof. Dr. Hildegard T. Greinix. Head of the Division of Hematology of the Medical University Graz, Austria.

Speakers:

  • Professor Andrea Bacigalupo. Department of Hematology. Fondazione Policlinico Universitario A.Gemelli IRCCS Universita’ Cattolica del Sacro Cuore. Rome, Italy.
  • Xiao-Jun Huang. Professor, Director, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Dr Leo Luznik. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.

The video will be available for EBMT members on the e-learning platform.

Good Practices for evaluating quality, safety and efficacy of novel tissue and cellular therapies and products - EuroGTP II Methodologies and Tools

The webinar aimed to improve the scientific assessment of novel products/processes/clinical indications and associated risks and promote the correct definition of evaluation protocols to guarantee its safe implementation.

Programme:
  • Introduction to EuroGTP methodologies (Richard Lomas)
  • Practical cases (Aurora Vassanelli)
  • Discussion - Q&A - (Moderator: Jaime Tabera)
  • Impact and continuity of EuroGTP II Project– (Rita Piteira)

By the end of this training participants should be able:

  • Correctly assess the novelty of a TCTP.
  • Understand the different risk factors and risk consequences associated with the TE’s activities and clinical application of Substances of Human Origin.
  • Perform objective risk analysis based on the rationale proposed by EuroGTP II – by evaluating the risks resulting from all aspects of T&C supply chain (from donor selection to clinical application) of the final product.
  • Design appropriate studies proportionate to the level of residual/unknown risk to confirm that the TCTP is safe and effective.
  • Understand the value of the Tissue & Cell Database.
Speaker panel:

Moderators:

  • Anne-Marie van Walraven. TRIP office for Hemo and Biovigilance and at Sanquin Blood Supply, currently as privacy coordinator of the the Blood Bank. Netherlands.
  • Jaime Tabera. Operations and Quality Assurance Manager, Barcelona Tissue Bank (BTB) of Banc de Sang I Teixits (BST), Catalonia, Spain

Speakers:

  • Richard Lomas. Senior Clinical Development Scientist, National Health Service - Blood and Transplant (NHSBT), Tissue and Eye Services, UK.
  • Aurora Vassanelli. Medical Director of the Verona Integrated University Hospital, Banca tessuti e Cellule Staminali UOC Medicina Trasfusionale Ospedale Policlinico Borgo Roma, Verona, Italy.
  • Rita Piteira. Project Coordinator, Barcelona Tissue Bank (BTB) of Banc de Sang I Teixits (BST), Catalonia, Spain.

Role of ECP in treatment of GvHD in the Ruxolitinib-era

The webinar was hosted by Dr Hildegard T. Greinix.

Recently, new immunosuppressive drugs have been approved for treatment of acute and chronic GvHD that is a serious complication of allogeneic HCT. Despite this fact, extracorporeal photopheresis remains an important, efficient and safe part of GvHD treatment strategies. This webinar will discuss the role of ECP in the current situation.

The video and slides are available for EBMT members on the e-learning platform.

Hormonal replacement therapy in iatrogenic gonadal insufficiency after HSCT: practical recommendations

The webinar was organized by the PDWP, hosted by Dr Alessandro Cattoni and moderated by Dr Adriana Balduzzi.

The learning objectives were:

  • ​How to perform a complete assessment of gonadal function in transplanted patients.
  • Learning a “risk-based” approach to assess and follow-up ovarian function after HSCT.
  • Which are the indications of hormonal replacement therapy after HSCT.
  • Management of hormonal replacement therapy: formulations, timing and doses.
  • How to diagnose and manage pre-clinical gonadal impairment.

The video and slides are available for EBMT members on the e-learning platform.

How to transplant patients with Sickle Cell disease in 2021

The webinar was organized by the PDWP, hosted by Dr Selim Corbacioglu and moderated by Dr Josu De La Fuente.

This recorded webinar will give you a step-by-step approach on how to approach hematopoietic stem cell transplantation and gene editing for sickle cell disease. It will highlight the pitfalls and particularities in the care of these utmost complicated patients as well as the specific transplant-related complications.

The video and slides are available for EBMT members on the e-learning platform.

 

Maintenance therapy after allogeneic SCT in AML

The live webinar was hosted by Dr Andreas Burchert and moderated by Dr Ali Barzabachi.

The learning objectives were:

  • What is the post HSCT standard of care and which patients are of high risk of relapse?
  • What is the available evidence to perform a post HSCT maintenance therapy in AML?
  • What types of treatments are available (targeted vs. non targeted)?
  • What is the achievable benefit vs. risks?
  • What is the future post HSCT maintenance treatment spectrum?

The video and slides are available for EBMT members on the e-learning platform.

Role of ATG/ATLG in stem cell transplantation

The live webinar was hosted by Dr Francesca Bonifazi and moderated by Dr Grzegorz Basak.

The learning objectives were:

  • Mandatoriness of GVHD prevention because of impact of GVHD on survival
  • Literature evidences on ATG/ATLG as GVHD prevention strategy
  • Mechanisms of action of ATG/ATLG
  • Quality of life after ATG/ATLG treatment
  • Open issues to increase outcome and knowledge about dosing and schedule

The video and slides are available for EBMT members on the e-learning platform.

Past workshops

Statistical Course - 2021 Edition

Basic course in the use of statistical methods to analyse stem cell transplantation data.

It had two parts:

  1. Collection of data, simple comparative analyses. Speaker: Richard Szydlo.

The first session covered the following topics:

  • Best data collection practices using Excel and Access
  • Basic descriptive and comparative statistical methods using a live analysis of data (with SPSS)
  • Optimum methods for collecting data that require statistical analysis
  • A review of the most commonly used statistical methods to describe and compare groups
  1. Essential survival analysis methods. Speaker: Antonella Santucci. 

The second session covered the following topics:

  • Interval Time of follow-up and the status variable (censored/event observations)
  • How to collect data 
  • The survival function
  • Kaplan-Meier curves and the log rank test
  • An introduction to Cox proportional hazard model
  • Demonstrative exercises will be done by  using SPSS vers.25.
IMPORTANT INFORMATION:

One week before the event, all participants received access to on-demand content regarding theoretical information of “Essential survival analysis methods”. During the live event, more practical aspects were explained and there was time for questions and answers.

On-demand material and attendance certificate is available to consult for registered participants on the e-learning platform. 

Speakers:

  • Dr Richard Szydlo, Medical Statistician, Department of Haematology, Imperial College, London, UK.
  • Dr Antonella SantucciHaemathology Institut University of Study of Perugia.

EBMT Benchmarking: The What, How and When?

The EBMT Clinical Outcomes Group (COG) has developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. In November 2020, centres received the first data-completeness reports. This webinar will explain the origins and methodology of the model, the centre perspective and the next steps. The webinar will be an opportunity for users to address questions to the expert panel and to give feedback on this first report. This feedback will be taken into account for the next phase of this project.

Learning Objectives:
  • Understand the basis of the benchmarking model

  • Learn to interpret the data-completeness report

  • Hear of future plans for the model

Speaker panel:

Chair: 

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.

Speakers: 

  • Prof. Dr. Hein Putter. Biostatistician, Leiden University Medical Center, Leiden, The Netherlands.

  • Riccardo Saccardi, MD. Director, Cell Therapy and Transfusion Medicine Unit. Careggi University Hospital, Firenze, Italy.

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.

Q&A Section: 

  • Prof. Dr. Hein Putter. Biostatistician, Leiden University Medical Center, Leiden, The Netherlands.

  • Riccardo Saccardi, MD. Director, Cell Therapy and Transfusion Medicine Unit. Careggi University Hospital, Firenze, Italy.

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.
  • Dirk-Jan Eikema. Biostatistician specialized in survival analysis. EBMT.

  • Isabel Sánchez-Ortega. Medical Officer. EBMT

Sponsorship

There are various opportunities to support the EBMT Educational Webinars. For more information, please send an email to fundraising@ebmt.org